The 2013 Seville Consensus Document on alternatives to allogenic blood transfusion. An update on the Seville Document;2013. Documento Sevilla de Consenso sobre Alternativas a la Transfusión de Sangre Alogénica. Actualización del Documento Sevilla

Revista Espanola de Anestesiologia y Reanimacion

Volumn 60, Issue 5, 2013, Pages

  Leal Noval, S R ^a   Munoz M ^a   Asuero, M ^a   Contreras, E ^a   Garcia Erce J A ^a   Llau, J V ^a   Moral, V ^a   Paramo J A ^a   Quintana, M ^a   Basora, M ^a   Bautista Paloma, F J ^a   Bisbe, E ^a   Boveda J L ^a   Castillo Munoz A ^a   Colomina, M J ^a   Fernandez C ^a   Fernandez Mondejar E ^a   Ferrandiz C ^a   Garcia de Lorenzo A ^a   Gomar, C ^a   Gomez Luque A ^a   Izuel, M ^a   Jimenez Yuste V ^a   Lopez Briz E ^a   Lopez Fernandez M L ^a   Martin Conde J A ^a   Montoro Ronsano, B ^a   Paniagua, C ^a   Romero Garrido, J A ^a   Ruiz, J C ^a   Salinas Argente, R ^a   Sanchez C ^a   Torrabadella, P ^a   Arellano, V ^a   Candela, A ^a   Fernandez J A ^a   Fernandez Hinojosa E ^a   Puppo, A ^a   more..

^a Sociedad Española de Medicina Intensiva Crítica y Unidades Coronarias ^*  (Spain)

Author keywords

Alternatives to allogeneic blood transfusion; Anemia; Fibrinogen; Haemoglobin

Indexed keywords

BLOODLESS CARE; CONSENSUS DEVELOPMENT; HUMAN; PRACTICE GUIDELINE; STANDARDS;

BLOODLESS MEDICAL AND SURGICAL PROCEDURES; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 84877827516     PISSN: 00349356     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redar.2012.12.003     Document Type: Article

References (222)

1. Leal R., Alberca I., Asuero M.S., Bóveda J.L., Carpio N., Contreras E., et al. Documento «Sevilla» de consenso sobre alternativas a la transfusión de sangre alogénica. Med Clin (Barc) 2006, 127(Supl 1):3-20.
2. Guyatt G.H., Oxman A.D., Kunz R., Falck-Ytter Y., Vist G.E., Liberati A., et al. Going from evidence to recommendations. BMJ 2008, 336:1049-1051.
3. Jaeschke R., Guyatt G.H., Dellinger P., Schünemann H., Levy M.M., Kunz R., et al. Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive. BMJ 2008, 337:a744.
4. Guyatt G., Gutterman D., Baumann M.H., Addrizzo-Harris D., Hylek E.M., Phillips B., et al. Grading strength of recommendations and quality of evidence in clinical guidelines: Report from an American College of Chest Physicians task force. Chest 2006, 129:174-181.
5. Hébert P.C., Wells G., Blajchman M.A., Marshall J., Martin C., Pagliarello G., et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical CareTrials Group. N Engl J Med 1999, 340:409-417.
6. Lacroix J., Hébert P.C., Hutchison J.S., Hume H.A., Tucci M., Ducruet T., et al. Transfusion strategies for patients in pediatric intensive care units. N Engl J Med 2007, 356:1609-1619.
7. Grover M., Talwalkar S., Casbard A., Boralessa H., Contreras M., Boralessa H., et al. Silent myocardial ischaemia and haemoglobin concentration: A randomized controlled trial of transfusion strategy in lower limb arthroplasty. Vox Sang 2006, 90:105-112.
8. Carson J.L., Grossman B.J., Kleinman S., Tinmouth A.T., Marques M.B., Fung M.K., et al. Red blood cell transfusion: A clinical practical guideline from the AABB. Ann Intern Med 2012, 157:49-58.
9. Gerbert D.R. Transfusion of packed red blood cells in patients with ischemic heart disease. Crit Care Med 2008, 36:1068-1074.
10. Wu W.C., Rathore S.S., Wang Y., Radford M.J., Krumholz H.M. Blood transfusion in elderly patients with acute myocardial infarction. N Engl J Med 2001, 345:1230-1236.
11. Sabatine M.S., Morrow D.A., Giugliano R.P., Burton P.B., Murphy S.A., Gibson C.M., et al. Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation 2005, 111:2042-2049.
12. Möhnle P., Snyder-Ramos S.A., Miao Y., Kulier A., Böttiger B.W., Levin J., et al. Postoperative red blood cell transfusion and morbid outcome in uncomplicated cardiac surgery patients. Intensive Care Med 2011, 37:97-109. Multicenter Study of Perioperative Ischemia [McSPI] Research Group.
13. Haijar L.A., Vincent J.L., Galas F.R., Nakamura R.E., Silva C.M., Santos M.H., et al. Transfusion requirements after cardiac surgery: The TRACS randomized controlled trial. JAMA 2010, 304:1559-1567.
14. Carson J.L., Terrin M.L., Noveck H., Sanders D.W., Chaitman B.R., Rhoads G.G., et al. Liberal or restrictive transfusion in high-risk patients after hip surgery. N Engl J Med 2011, 365:2453-2462.
15. Leal-Noval S.R., Jiménez-Sánchez M. La transfusion de hematíes incrementa la oxigenación tisular y mejora el resultado clínico (con). Med Intensiva 2010, 34:471-475.
16. Kramer A.H., Zygun D.A. Anemia and red blood cell transfusion in neurocritical care. Crit Care 2009, 13:R89.
17. Leal-Noval S.R., Múñoz-Gómez M., Murillo-Cabezas F. Optimal hemoglobin concentration in patients with subarachnoid hemorrhage, acute ischemic stroke and traumatic brain injury. Curr Opin Crit Care 2008, 14:156-162.
18. Carless P., Moxey A., O'Connell D., Henry D. Autologous transfusion techniques: A systematic review of their efficacy. Transfus Med 2004, 14:123-144.
19. Bierbaum B.E., Callaghan J.J., Galante J.O., Rubash H.E., Tooms R.E., Welch R.B. An analysis of blood management in patients having a total hip or knee arthroplasty. J Bone Joint Surg Am 1999, 81:2-10.
20. Feagan B.G., Wong C.J., Johnston W.C., Arellano R., Colterjohn N., Karkouti K., et al. Transfusion practices for elective orthopedic surgery. CMAJ 2002, 166:310-314.
21. Rosencher N., Kerkkamp H.E., Macheras G., Munuera L.M., Menichella G., Barton D.M., et al. Orthopedic Surgery Transfusion Hemoglobin European Overview (OSTHEO) study: Blood management in elective knee and hip arthroplasty in Europe. Transfusion 2003, 43:459-469.
22. Freedman J., Luke K., Escobar M., Vernich L., Chiavetta J.A. Experience of a network of transfusion coordinators for blood conservation (Ontario Transfusion Coordinators [ONTraC]). Transfusion 2008, 48:237-250.
23. Keating E.M., Callaghan J.J., Ranawat A.S., Bhirangi K., Ranawat C.S. A randomized, parallel-group, open-label trial of recombinant human erythropoietin vs preoperative autologous donation in primary total joint arthroplasty: Effect on postoperative vigor and handgrip strength. J Arthroplasty 2007, 22:325-333.
24. Woolson S.T., Wall W.W. Autologous blood transfusion after total knee arthroplasty: A randomized, prospective study comparing predonated and postoperative salvage blood. J Arthroplasty 2003, 18:243-249.
25. Ridgeway S., Tai C., Alton P., Barnardo P., Harrison D.J. Pre-donated autologous blood transfusion in scoliosis surgery. J Bone Joint Surg Br 2003, 85:1032-1036.
26. Bess R.S., Lenke L.G., Bridwell K.H., Steger-May K., Hensley M. Wasting of preoperatively donated autologous blood in the surgical treatment of adolescent idiopathic scoliosis. Spine (Phila Pa 1976) 2006, 31:2375-2380.
27. Franchini M., Gandini G., Regis D., de Gironcoli M., Cantini M., Aprili G. Recombinant human erythropoietin facilitates autologous blood collections in children undergoing corrective spinal surgery. Transfusion 2004, 44:1122-1124.
28. García-Erce J.A., Solano V.M., Sáez M., Muñoz M. Recombinant human erythropoietin facilitates autologous blood donation in children undergoing corrective spinal surgery. Transfusion 2005, 45:820-821.
29. Goodnough L.T., Marcus R.E. Erythropoiesis in patients stimulated with erythropoietin: The relevance of storage iron. Vox Sang 1998, 75:128-133.
30. Dietrich W., Thuermel K., Heyde S., Busley R., Berger K. Autologous blood donation in cardiac surgery: Reduction of allogeneic blood transfusion and cost-effectiveness. J Cardiothorac Vasc Anesth 2005, 19:589-596.
31. Muñoz M., Campos A., García-Erce J.A. Intravenous iron in colorectal cancer surgery. Semin Hematol 2006, 43(Suppl 6):S36-S38.
32. Waters J.H., Lee J.S., Klein E., O'Hara J., Zippe C., Potter P.S. Preoperative autologous donation versus cell salvage in the avoidance of allogeneic transfusion in patients undergoing radical retropubic prostatectomy. Anesth Analg 2004, 98:537-542.
33. Ishizawa T., Hasegawa K., Tsuno N.H., Tanaka M., Mise Y., Aoki T., et al. Predeposit autologous plasma donation in liver resection for hepatocellular carcinoma: Toward allogenic blood-free operations. J Am Coll Surg 2009, 209:206-214.
34. Comité de Acreditación en Transfusión (CAT). Estándares de Acreditación. 3a ed. Grupo Acción Médica; 2006.
35. Real Decreto 1088/2005 de 16 de septiembre, por el que se establecen los requisitos técnicos y condiciones mínimas de la hemodonación y de los centros y servicios de transfusión. BOE núm 225 de 20/9/2005.
36. Segal J.B., Blasco-Colmenares E., Norris E.J., Guallar E. Preoperative acute normovolemic hemodilution: A meta-analysis. Transfusion 2004, 44:632-644.
37. Mehr-Aein A., Davoodi S., Madani-Civi M. Effects of tranexamic acid and autotransfusion in coronary artery bypass. Asian Cardiovasc Thorac Ann 2007, 15:49-53.
38. Sociedad Española de Transfusión Sanguínea y Terapia Celular. Guía sobre la transfusión de componentes sanguíneos y derivados plasmáticos.4a ed. Barcelona: Sociedad Española de Transfusión Sanguínea; 2010.
39. Karkouti K., Beatties W.S., Wijeysundera D.N., Rao V., Chan C., Dattilo K.M., et al. Hemodilution during cardiopulmonary bypass is an independent risk factor for acute renal failure in adult cardiac surgery. Thorac Cardiovasc Surg 2005, 129:391-400.
40. Wypij D., Jonas R.A., Bellinger D.C., del Nido P.J., Mayer J.E., Bacha E.A., et al. The effect of hematocrit during hypothermic cardiopulmonary bypass in infant heart surgery: Results from the combined Boston hematocrit trials. J Thorac Cardiovasc Surg 2008, 135:355-360.
41. Bennett J., Haynes S., Torella F., Grainger H., McCollum C. Acute normovolemic hemodilution in moderate blood loss surgery: A randomized controlled trial. Transfusion 2006, 46:1097-1103.
42. Thomas D., Wareham K., Cohen D., Hutchings H. Autologous blood transfusion in total knee replacement surgery. Br J Anaesth 2001, 86:669-673.
43. Muñoz M., Ariza D., Florez A., Campos A. Reinfusion drains reduce postoperative transfusion requirements after primary total knee replacement surgery. Transfus Med 2008, 18:269-271.
44. Mirza S.B., Campion J., Dixon J.H., Panesar S.S. Efficacy and economics of postoperative blood salvage in patients undergoing elective total hip replacement. Ann R Coll Surg Engl 2007, 89:777-784.
45. Trujillo M.M., Carrero A., Muñoz M. The utility of the perioperative autologous transfusion system OrthoPAT in total hip replacement surgery: A prospective study. Arch Orthop Trauma Surg 2008, 128:1031-1038.
46. Phillips S.J., Chavan R., Porter M.L., Kay P.R., Hodgkinson J.P., Purbach B., et al. Does salvage and tranexamic acid reduce the need for blood transfusion in revision hip surgery?. J Bone Joint Surg Br 2006, 88:1141-1142.
47. Sebastián C., Romero R., Olalla E., García-Vallejo J.J., Muñoz M. Postoperative blood salvage and reinfusion in spinal surgery: Blood quality, effectiveness and impact on patient blood parameters. Eur Spine J 2000, 9:458-465.
48. Gause P.R., Siska P.A., Westrick E.R., Zavatsky J., Irrgang J.J., Kang J.D. Efficacy of intraoperative cell saver in decreasing postoperative blood transfusions in instrumented posterior lumbar fusion patients. Spine (Phila Pa 1976) 2008, 33:571-575.
49. Mirza A.H., Aldlyami E., Bhimarasetty C., Thompson A.G., Spilsbury J., Marks D.S. The role of peri-operative cell salvage in instrumented anterior correction of thoracolumbar scoliosis: A case-controlled study. Acta Orthop Belg 2009, 75:87-93.
50. Rubens F.D., Boodhwani M., Mesana T., Wozny D., Wells G., Nathan H.J. The cardiotomy trial: A randomized, double-blind study to assess the effect of processing of shed blood during cardiopulmonary bypass on transfusion and neurocognitive function. Circulation 2007, 116(11 Suppl):I89-I97. Cardiotomy Investigators.
51. Murphy G.J., Allen S.M., Unsworth-White J., Lewis C.T., Dalrymple-Hay M.J. Safety and efficacy of perioperative cell salvage and autotransfusion after coronary artery bypass grafting: A randomized trial. Ann Thorac Surg 2004, 77:1553-1559.
52. Murphy G.J., Rogers C.S., Lansdowne W.B., Channon I., Alwair H., Cohen A., et al. Safety, efficacy, and cost of intraoperative cell salvage and autotransfusion after off-pump coronary artery bypass surgery: A randomized trial. J Thorac Cardiovasc Surg 2005, 130:20-28.
53. Tawfick W.A., O'Connor M., Hynes N., Sultan S. Implementation of the Continuous AutoTransfusion System (C.A.T.S) in open abdominal aortic aneurysm repair: An observational comparative cohort study. Vasc Endovascular Surg 2008, 42:32-39.
54. Serracino-Inglott F., Awad S., Barclay A., Nasim A. The use of a cell saver during repair of ruptured abdominal aortic aneurysms increases early survival. Ann R Coll Surg Engl 2005, 87:475.
55. Donayre C., Adimora U., Song T., Kopchok G., Lippmann M., White R. Impact of an autotransfusion system during endoluminal repair of abdominal aortic aneurysms: Does it decrease the use of allogeneic blood?. Am Surg 2005, 71:786-790.
56. Nieder A.M., Carmack A.J., Sved P.D., Kimm S.S., Manoharan M., Soloway M.S., et al. Intraoperative cell salvage during radical prostatectomy is not associated with greater biochemical recurrence rate. Urology 2005, 65:730-734.
57. Rebarber A., Lonser R., Jackson S., Copel J.A., Sipes S. The safety of intraoperative autologous blood collection and autotransfusion during cesarean section. Am J Obstet Gynecol 1998, 179:715-720.
58. Priuli G., Darate R., Perrin R.X., Lankoande J., Drouet N. Multicentre experience with a simple blood salvage technique in patients with ruptured ectopic pregnancy in sub-Sahelian West Africa. Vox Sang 2009, 97:317-323.
59. Bowley D.M., Barker P., Boffard K.D. Intraoperative blood salvage in penetrating abdominal trauma: A randomised, controlled trial. World J Surg 2006, 30:1074-1080.
60. Muñoz M., Slappendel R., Thomas D. Laboratory characteristics and clinical utility of post-operative cell salvage: Washed or unwashed blood transfusion?. Blood Transfus 2011, 9:248-261.
61. Waters J.H., Yazer M., Chen Y.F., Kloke J. Blood salvage and cancer surgery: A meta-analysis of available studies. Transfusion 2012, 52:2167-2173.
62. Johansson P.I. Coagulation monitoring of the bleeding traumatized patient. Curr Opin Anesthesiol 2012, 25:235-241.
63. Kozek-Langeneckerr S.A. Perioperative coagulation monitoring. Best Pract Res Clin Anaesth 2010, 24:27-40.
64. Frith D., Davenport R., Brohi K. Acute traumatic coagulopathy. Curr Opin Anesthesiol 2012, 25:229-234.
65. Görlinger K., Dirkmann D., Hanke A.A., Kamler M., Kottenberg E., Thielmann M., et al. First-line therapy with coagulation factor concentrates combined with point-of-care coagulation testing is associated with decreased allogeneic blood transfusion in cardiovascular surgery: A retrospective, single-center cohort study. Anesthesiology 2011, 115:1179-1191.
66. Levy J.H., Szlam F., Tanaka K.A., Sniecienski R.M. Fibrinogen and hemostatic target for the management of acquired bleeding. Anesth Analg 2012, 114:261-274.
67. Afshari A., Wikkelsø A., Brok J., Møller A.M., Wetterslev J. Thrombelastography (TEG) or thromboelastometry (ROTEM) to monitor haemotherapy versus usual care in patients with massive transfusion. Cochrane Database Syst Rev 2011, 3:CD007871.
68. Kalina U., Bickard H., Schulte S. Biochemical comparison of seven commercially available prothrombin concentrates. Int J Clin Pract 2008, 62:1614-1622.
69. Bhagirath U.C., O'Malley L., Crowther M.A. Management of bleeding complications in the anticoagulated patient. Semin Hematol 2011, 48:285-294.
70. Pabinger I., Brenner B., Kalina U., Knaub S., Nagy A., Ostermann H. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal; a prospective multinational clinical trial. J Thromb Haemost 2008, 6:622-631.
71. Lankiewicz M.W., Hays J., Friedman K.D., Tinkoff G., Blatt P.M. Urgent reversal of warfarin with prothrombin complex concentrate. J Thromb Haemost 2006, 4:967-970.
72. Lubetsky A., Hoffman R., Zimlichman R., Eldor A., Zvi J., Kostenko V., et al. Efficacy and safety of a prothrombin complex concentrate (Octaplex) for rapid reversal of oral anticoagulation. Thromb Res 2004, 113:371-378.
73. Holbrook A., Schulman S., Witt D.M., Vandvik P.O., Fish J., Kovacs M.J., et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thormbosis, 9th ed: American College of Chest Pysicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141(2 Suppl):e152S-e184S.
74. Ferraris V.A., Brown J.R., Despotis G.J., Hammon J.W., Reece T.B., Saha S.P., et al. 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg 2011, 91:944-982. Society of Thoracic Surgeons Blood Conservation Guideline Task Force; Society of Cardiovascular Anesthesiologists Special Task Force on Blood Transfusion; International Consortium for Evidence Based Perfusion.
75. Cucchiara B., Messe S., Sansing L., Kasner S., Lyden P. Hematoma growth in oral anticoagulant related intracerebral hemorrhage. Stroke 2008, 39:2993-2996.
76. Flaherty M.L., Tao H., Haverbusch M., Sekar P., Kleindorfer D., Kissela B., et al. Warfarin use leads to larger intracerebral hematomas. Neurology 2008, 71:1084-1089.
77. Aiyagari V., Testai F.D. Correction of coagulopathy in warfarin associated cerebral hemorrhage. Curr Opin Crit Care 2009, 15:87-92.
78. Kuwashiro T., Yasaka M., Itabashi R., Nakagaki H., Miyashita F., Naritomi H., et al. Enlargement of acute intracerebral hematomas in patients on long-term warfarin treatment. Cerebrovasc Dis 2010, 29:446-453.
79. Morgenstern L.B., Hemphill J.C., Anderson C., Becker K., Broderick J.P., Connolly E.S., et al. Guidelines for the management of spontaneous intracerebral hemorrhage: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2010, 41:2108-2129. American Heart Association Stroke Council and Council on Cardiovascular Nursing.
80. Goodnough L.T., Shander A. How I treat warfarin-associated coagulopathy in patients with intracerebral hemorrhage. Blood 2011, 117:6091-6099.
81. Huttner H.B., Schellinger P.D., Hartmann M., Köhrmann M., Juettler E., Wikner J., et al. Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: Comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke 2006, 37:1465-1470.
82. Siddiq F., Jalil A., McDaniel C., Brock D.G., Pineda C.C., Bell R.D., et al. Effectiveness of Factor IX complex concentrate in reversing warfarin associated coagulopathy for intracerebral hemorrhage. Neurocrit Care 2008, 8:36-41.
83. Godier A., Samana C.M. Plasma/platelets/red blood cell ratio in the management of the bleeding traumatized patient. Does it matter?. Curr Opin Anaesthesiol 2012, 25:242-247.
84. Dirks J., Jorgensen H., Jensen C.H., Osttowski S.R., Johansson P.I. Blood product ratio in acute traumatic coagulopathy effect in a Scandinavian level 1 trauma center. Scand J Trauma Resusc Emerg Med 2010, 18:65.
85. Joseph B., Amini A., Friese R.S., Houdek M., Hays D., Kulvatunyou N., et al. Factor IX complex for the correction of traumatic coagulopathy. J Trauma Acute Care Surg 2012, 72:828-834.
86. Schick K.S., Fertmann J.M., Jauch K.W., Hoffmann J.N. Prothrombin complex concentrate in surgical patients: Retrospective evaluation of vitamin K antagonist reversal and treatment of severe bleeding. Crit Care 2009, 13:R191.
87. Lorenz R., Kienast J., Otto U., Egger K., Kiehl M., Schreiter D., et al. Efficacy and safety of a prothrombin complex concentrate with two virus-inactivation steps in patients with severe liver damage. Eur J Gastroenterol Hepatol 2003, 15:15-20.
88. Chowdhury P., Saayman A.G., Paulus U., Findlay G.P., Collins P.W. Efficacy of standard dose and 30ml/Kg fresh frozen plasma in correcting laboratory parameters of haemosthasis in critically ill patients. Br J Haematol 2004, 125:69-73.
89. Leal-Noval S.R., Arellano V., Maestre A., Múñoz M., Fernández V., Ferrándiz C., et al. Impact of national transfusion indicators on appropriate blood usage in critically ill patients. Transfusion 2011, 51:1957-1965.
90. Illanes S., Zhou W., Schwarting S., Heiland S., Veltkamp R. Comparative effectiveness of hemostatic therapy in experimental warfarin-associated intracerebral hemorrhage. Stroke 2011, 42:191-195.
91. Yuan Z.H., Jiang J.K., Huang W.D., Zhu J.Y., Wang J.Z. A meta-analysis of the efficacy and safety of recombinant activated factor vii for patients with acute intracerebral hemorrhage without hemophilia. J Clin Neurosci 2010, 17:685-693.
92. Khorsand N., Veeger N.J., Muller M., Overdiek J.W., Huisman W., van Herst R.M., et al. Fixed versus variable dose of prothrombin complex concentrate for counteracting vitamin K antagonist therapy. Tranfus Med 2011, 21:116-123.
93. Vigué D. Bench-to-bedside review: Optimising emergency reversal of vitamin K antagonists in severe haemorrhage - from theory to practice. Crit Care 2009, 13:209.
94. Sorensen B., Spahn D.R., Innerhofer P., Spannagl M., Rossaint R. Clinical review: Prothrombin complex concentrates, evaluation of safety and thrombogenicity. Crit Care 2011, 15:201.
95. Rahe-Meyer N., Sorensen B. Fibrinogen concentrate for management of bleeding. J Thromb Haemost 2011, 9:1-5.
96. Ozier Y., Hunt B.J. Fibrinogen concentrate for management of bleeding: Against indiscriminate use. J Thromb Haemost 2011, 9:6-8.
97. Solomon C., Pichlmaier U., Schoechl H., Hagl C., Raymondos K., Scheinichen D., et al. Recovery of fibrinogen after administration of fibrinogen concentrate to patients with severe bleeding after cardiopulmonary bypass surgery. Br J Anaesth 2010, 104:555-562.
98. Fries D., Martini W.Z. Role of fibrinogen in trauma-induced coagulopathy. Br J Anaesth 2010, 105:116-121.
99. Rossaint R., Bouillon B., Lerny V., Coats T.J., Duranteau J., Fernández-Mondéjar E., et al. Management of bleeding following major trauma: An updated European guideline. Crit Care 2010, 14:R52.
100. Stinger H.K., Spinella P.C., Perkins J.G., Grathwohl K.W., Salinas J., Martini W.Z., et al. The ratio of fibrinogen to red blood cell transfused affects survival in casualties receiving massive transfusions at an army combat support hospital. J Trauma 2008, 64(2 Suppl):S79-S85.
101. Schöchl H., Nienaber U., Maegele M., Hochleitner G., Primavesi F., Steitz B., et al. Transfusion in trauma: Thromboelastometry-guided coagulation factor concentrate-based therapy versus standard fresh frozen plasma-based therapy. Crit Care 2011, 15:R83.
102. Mell M.W., O'Neil A.S., Callcut R.A., Acher C.W., Hoch J.R., Tefera G., et al. Effect of early plasma transfusion on mortality in patients with ruptura abdominal aortic aneurism. Surgery 2010, 148:955-962.
103. Lancé M.D., Ninivaggi M., Schols S.E., Feijge M.A., Oehrl S.K., Kuiper G.J., et al. Perioperative dilutional coagulopathy treated with fresh frozen plasma and fibrinogen concentrate: A prospective randomized intervention trial. Vox Sang 2012, 103:25-34.
104. Fenger-Eriksen C., Jensen T.M., Kristensen T.M., Jensen K.M., Tonnesen E., Ingerslev J., et al. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: A randomized, placebo-controlled clinical trial. J Thromb Haemost 2009, 7:795-802.
105. Bell S.F., Rayment R., Collins P.W., Collins R.E. The use of fibrinogen concentrate to correct hypofibrinogenaemia rapidly during obstetric haemorrhage. Int J Obstet Anaesth 2010, 19:218-223.
106. Weiss G., Lison S., Glaser M., Herberger S., Johanning K., Strasser T., et al. Observational study of fibrinogen concentrate in massive hemorrhage: Evaluation of a multicenter register. Blood Coagul Fibrinolysis 2011, 22:727-734.
107. Ogawa S., Szlam F., Chen E.P., Nishimura T., Kim H., Roback J.D., et al. A comparative evaluation of rotation thromboelastometry and standard coagulation tests in hemodilution-induced coagulation changes after cardiac surgery. Transfusion 2012, 52:14-22.
108. Fernández-Hinojosa E., Murillo-Cabezas F., Puppo-Moreno A., Leal-Noval S.R. Alternativas terapéuticas de la hemorragia masiva. Med Intensiva 2012, 36:496-503.
109. Sukeik M., Alshryda S., Haddad F.S., Mason J.M. Systematic review and meta-analysis of the use of tranexamic acid in total hip replacement. J Bone Joint Surg Br 2011, 93:39-46.
110. Alshryda S., Sarda P., Sukeik M., Nargol A., Blenkinsopp J., Mason J.M. Tranexamic acid in total knee replacement: A systematic review and meta-analysis. J Bone Joint Surg Br 2011, 93:1577-1585.
111. Ipema H.J., Tanzi M.G. Use of topical tranexamic acid or aminocaproic acid to prevent bleeding after major surgical procedures. Ann Pharmacother 2012, 46:97-107.
112. Wong J., el Beheiry H., Rampersaud Y.R., Lewis S., Ahn H., de Silva Y., et al. Tranexamic acid reduces perioperative blood loss in adult patients having spinal fusion surgery. Anesth Analg 2008, 107:1479-1486.
113. Elwatidy S., Jamjoom Z., Elgamal E., Zakaria A., Turkistani A., el-Dawlatly A. Efficacy and safety of prophylactic large dose of tranexamic acid in spine surgery: A prospective, randomized, double-blind, placebo-controlled study. Spine (Phila Pa 1976) 2008, 33:2577-2580.
114. Sethna N.F., Zurakowski D., Brustowicz R.M., Bacsik J., Sullivan L.J., Shapiro F. Tranexamic acid reduces intraoperative blood loss in pediatric patients undergoing scoliosis surgery. Anesthesiology 2005, 102:727-732.
115. Zufferey P., Merquiol F., Laporte S., Decousus H., Mismetti P., Auboyer C., et al. Do antifibrinolytics reduce allogeneic blood transfusion in orthopedic surgery?. Anesthesiology 2006, 105:1034-1046.
116. Henry D., Carless P., Fergusson D., Laupacis A. The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: A meta-analysis. CMAJ 2009, 180:183-193.
117. Adler Ma S.C., Brindle W., Burton G., Gallacher S., Hong F.C., Manelius I., et al. Tranexamic acid is associated with less blood transfusion in off-pump coronary artery bypass graft surgery: A systematic review and meta-analysis. J Cardiothorac Vasc Anesth 2011, 25:26-35.
118. Abrishami A., Chung F., Wong J. Topical application of antifibrinolytic drugs for on-pump cardiac surgery: A systematic review and meta-analysis. Can J Anaesth 2009, 56:202-212.
119. Fergusson D.A., Hébert P.C., Mazer C.D., Fremes S., MacAdams C., Murkin J.M., et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008, 358:2319-2331.
120. McIlroy D.R., Myles P.S., Phillips L.E., Smith J.A. Antifibrinolytics in cardiac surgical patients receiving aspirin: A systematic review and meta-analysis. Br J Anaesth 2009, 102:168-178.
121. Molenaar I.Q., Warnaar N., Groen H., Tenvergert E.M., Slooff M.J., Porte R.J. Efficacy and safety of antifibrinolytic drugs in liver transplantation: A systematic review and meta-analysis. Am J Transplant 2007, 7:185-194.
122. Wu C.C., Ho W.M., Cheng S.B., Yeh D.C., Wen M.C., Liu T.J., et al. Perioperative parenteral tranexamic acid in liver tumor resection: A prospective randomized trial toward a " blood transfusion" -free hepatectomy. Ann Surg 2006, 243:173-180.
123. Gungorduk K., Yi{dotless}ldi{dotless}ri{dotless}m G., Asi{dotless}ci{dotless}oĝlu O., Gungorduk O.C., Sudolmus S., Ark C. Efficacy of intravenous tranexamic acid in reducing blood loss after elective cesarean section: A prospective, randomized, double-blind, placebo-controlled study. Am J Perinatol 2011, 28:233-240.
124. Crescenti A., Borghi G., Bignami E., Bertarelli G., Landoni G., Casiraghi G.M., et al. Intraoperative use of tranexamic acid to reduce transfusion rate in patients undergoing radical retropubic prostatectomy: Double blind, randomised, placebo controlled trial. BMJ 2011, 343:d5701.
125. Shakur H., Roberts I., Bautista R., Caballero J., Coats T., Dewan Y., et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): A randomised, placebo-controlled trial. Lancet 2010, 376:23-32. CRASH-2 trial collaborators.
126. Morrison J.J., Dubose J.J., Rasmussen T.E., Midwinter M.J. Military Application of Tranexamic Acid in Trauma Emergency Resuscitation (MATTERs) Study. Arch Surg 2012, 147:113-119.
127. Henry D.A., O'Connell D.L. Effects of fibrinolytic inhibitors on mortality from upper gastrointestinal haemorrhage. BMJ 1989, 298:1142-1146.
128. Manji R.A., Grocott H.P., Leake J., Ariano R.E., Manji J.S., Menkis A.H., et al. Seizures following cardiac surgery: The impact of tranexamic acid and other risk factors. Can J Anaesth 2012, 59:6-13.
129. Montes F.R., Pardo D.F., Carreño M., Arciniegas C., Dennis R.J., Umaña J.P. Risk factors associated with postoperative seizures in patients undergoing cardiac surgery who received tranexamic acid: A case-control study. Ann Card Anaesth 2012, 15:6-12.
130. Carless P.A., Henry D.A., Moxey A.J., O'Connell D., McClelland B., Henderson K.M., et al. Desmopressing for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2004, 1. CD001884.
131. Aguado M.J., Molina J.M., Villegas R. Uso adecuado del factor vii activado recombinante en pacientes no hemofílicos 2010, Agencia de Evaluación de Tecnologías Sanitarias de Andalucía, Sevilla, AETSA 2007/04.
132. Zangrillo A., Mizzi A., Biondi-Zoccai G., Bignami E., Calabrò M.G., Pappalardo F., et al. Recombinant activated factor vii in cardiac surgery: A meta-analysis. J Cardiothorac Vasc Anesth 2009, 23:34-40.
133. Gill R., Herbertson M., Vuylsteke A., Olsen P.S., von Heymann C., Mythen M., et al. Safety and efficacy of recombinant activated factor vii: A randomized placebo-controlled trial in the setting of bleeding after cardiac surgery. Circulation 2009, 120:21-27.
134. Hauser C.J., Boffard K., Dutton R., Bernard G.R., Croce M.A., Holcomb J.B., et al. Results of the CONTROL trial: Efficacy and safety of recombinant activated Factor VII in the management of refractory traumatic hemorrhage. J Trauma 2010, 69:489-500. CONTROL Study Group.
135. Mayer S.A., Brun N.C., Begtrup K., Broderick J., Davis S., Diringer M.N., et al. Efficacy and safety of recombinant activated factor vii for acute intracerebral hemorrhage. N Engl J Med 2008, 358:2127-2137. FAST Trial Investigators.
136. Bosch J., Thabut D., Albillos A., Carbonell N., Spicak J., Massard J., et al. Recombinant factor viia for variceal bleeding in patients with advanced cirrhosis: A randomized, controlled study. Hepatology 2008, 47:1604-1614.
137. Yank V., Tuohy C.V., Logan A.C., Bravata D.M., Staudenmayer K., Eisenhut R., et al. Systematic review: Benefits and harms of in-hospital use of recombinant factor viia for off-label indications. Ann Intern Med 2011, 154:529-540.
138. Diringer M.N., Skolnick B.E., Mayer S.A., Steiner T., Davis S.M., Brun N.C., et al. Thromboembolic events with recombinant activated factor vii in spontaneous intracerebral hemorrhage: Results from the Factor Seven for Acute Hemorrhagic Stroke (FAST) trial. Stroke 2010, 41:48-53.
139. Levy M., Levy J., Andersen H., Truloff D. Safety of recombinant activated factor vii in randomized clinical trials. N Engl J Med 2010, 363:1791-1800.
140. Lidder P.G., Sanders G., Whitehead E., Douie W.J., Mellor N., Lewis S.J., et al. Pre-operative oral iron supplementation reduces blood transfusion in colorectal surgery - a prospective, randomised, controlled trial. Ann R Coll Surg Engl 2007, 89:418-421.
141. Okuyama M., Ikeda K., Shibata T., Tsukahara Y., Kitada M. Preoperative iron supplementation and intraoperative transfusion during colorectal cancer surgery. Surg Today 2005, 35:36-40.
142. Cuenca J., García-Erce J.A., Martínez F., Cardona R., Pérez-Serrano L., Muñoz M. Preoperative haematinics and transfusion protocol reduce the need for transfusion after total knee replacement. Int J Surg 2007, 5:89-94.
143. Rogers B.A., Cowie A., Alcock C., Rosson J.W. Identification and treatment of anaemia in patients awaiting hip replacement. Ann R Coll Surg Engl 2008, 90:504-507.
144. Mundy G.M., Birtwistle S.J., Power R.A. The effect of iron supplementation on the level of haemoglobin after lower limb arthroplasty. J Bone Joint Surg Br 2005, 87:213-217.
145. Parker M.J. Iron supplementation for anemia after hip fracture surgery: A randomized trial of 300 patients. J Bone Joint Surg Am 2010, 92:265-269.
146. Crosby L., Palarski V.A., Cottington E., Cmolik B. Iron supplementation for acute blood loss anemia after coronary artery bypass surgery: A randomized, placebo-controlled study. Heart Lung 1994, 23:493-499.
147. Pieracci F.M., Henderson P., Rodney J.R., Holena D.N., Genisca A., Benkert I.I.S., et al. Randomized, double-blind, placebo-controlled trial of effects of enteral iron supplementation on anemia and risk of infection during surgical critical illness. Surg Infect (Larchmt) 2009, 10:9-19.
148. Bisbe E., García-Erce J.A., Díez-Lobo A.I., Muñoz M. A multicentre comparative study on the efficacy of intravenous ferric carboxymaltose and iron sucrose for correcting preoperative anaemia in patients undergoing major elective surgery. Br J Anaesth 2011, 107:477-478.
149. Díaz-Espallardo C., Laso-Morales M.J., Colilles-Calvet C., Mora-López L., Roig-Martínez I., Martínez-Marín M.T. El abordaje multidisciplinar es útil para la optimización de la hemoglobina preoperatoria en cirugía neoplásica colorrectal. Cir Esp 2011, 89:392-399.
150. Edwards T.J., Noble E.J., Durran A., Mellor N., Hosie K.B. Randomized clinical trial of preoperative intravenous iron sucrose to reduce blood transfusion in anaemic patients after colorectal cancer surgery. Br J Surg 2009, 96:1122-1128.
151. Cuenca J., García-Erce J.A., Muñoz M., Izuel M., Martínez A.A., Herrera A. Patients with pertrochanteric hip fracture may benefit from preoperative intravenous iron therapy: A pilot study. Transfusion 2004, 44:1447-1452.
152. Cuenca J., García-Erce J.A., Martínez A.A., Solano V.M., Molina J., Muñoz M. Role of parenteral iron in the management of anaemia in the elderly patient undergoing displaced subcapital hip fracture repair: Preliminary data. Arch Orthop Trauma Surg 2005, 125:342-347.
153. Serrano-Trenas J.A., Font-Ugalde P., Muñoz-Cabello L., Castro-Chofles L., Rodríguez-Fernández P.J., Carpintero-Benítez P. Role of perioperative intravenous iron therapy in elderly hip fracture patients. A single center randomized controlled trial. Transfusion 2011, 51:97-104.
154. García-Erce J.A., Cuenca J., Muñoz M., Izuel M., Martínez A.A., Herrera A., et al. Perioperative stimulation of erythropoiesis with intravenous iron and erythropoietin reduces transfusion requirements in patients with hip fracture. A prospective observational study. Vox Sang 2005, 88:235-243.
155. García-Erce J.A., Cuenca J., Haman-Alcober S., Martínez A.A., Herrera A., Muñoz M. Efficacy of preoperative recombinant human erythropoietin administration for reducing transfusion requirements in patients undergoing surgery for hip fracture repair. An observational cohort study. Vox Sang 2009, 97:260-267.
156. Cuenca J., García-Erce J.A., Martínez F., Pérez-Serrano L., Herrera A., Muñoz M. Perioperative intravenous iron, with or without erythropoietin, plus restrictive transfusion protocol reduce the need for allogenic blood after knee replacement surgery. Transfusion 2006, 46:1112-1119.
157. Madi-Jebara S.N., Sleilaty G.S., Achouh P.E., Yasigi A.G., Hadad F.A., Hayek G.M., et al. Postoperative intravenous iron used alone or in combination with low-dose erythropoietin is not effective for correction of anemia after cardiac surgery. J Cardiothorac Vasc Anesth 2004, 18:59-63.
158. Muñoz M., Naveira E., Seara J., Cordero J. Effects of postoperative intravenous iron on transfusion requirements after lower limb arthroplasty. Br J Anaesth 2012, 108:532-534.
159. Berniére J., Dehullu J.P., Gall O., Murat I. Intravenous iron in the treatment of postoperative anemia in surgery of the spine in infants and adolescents. Rev Chir Orthop Reparatrice Appar Mot 1998, 84:319-322.
160. Gredilla E., Gimeno M., Canser E., Martínez B., Pérez Ferrer A., Gilsanz F. Tratamiento de la anemia en el postparto y en el postoperatorio inmediato de cirugía ginecológica, con hierro intravenoso. Rev Esp Anestesiol Reanim 2006, 53:208-213.
161. Armand-Ugón R., Cheong T., Matapandewu G., Rojo-Sanchís A., Bisbe E., Muñoz M. Efficacy of intravenous iron for treating postpartum anemia in low-resource African countries: A pilot study in Malawi. J Womens Health (Larchmt) 2011, 20:123-127.
162. Bhandal N., Russell R. Intravenous versus oral iron therapy for postpartum anaemia. BJOG 2006, 113:1248-1252.
163. Westad S., Backe B., Salvesen K.A., Nakling J., Okland I., Borthen I., et al. A 12-week randomised study comparing intravenous iron sucrose versus oral ferrous sulphate for treatment of postpartum anemia. Acta Obstet Gynecol Scand 2008, 87:916-923.
164. Van Wyck D.B., Martens M.G., Seid M.H., Baker J.B., Mangione A. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: A randomized controlled trial. Obstet Gynecol 2007, 110:267-278.
165. Seid M.H., Derman R.J., Baker J.B., Banach W., Goldberg C., Rogers R. Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: A randomized controlled clinical trial. Am J Obstet Gynecol 2008, 199:435.e1-435.e7.
166. Schröder O., Mickisch O., Seidler U., de Weerth A., Dignass A.U., Herfarth H., et al. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease--a randomized, controlled, open-label, multicenter study. Am J Gastroenterol 2005, 100:2503-2509.
167. Lindgren S., Wikman O., Befrits R., Blom H., Eriksson A., Grännö C., et al. Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: A randomized, controlled, evaluator-blind, multicentre study. Scand J Gastroenterol 2009, 44:838-845.
168. Kulnigg S., Stoinov S., Simanenkov V., Dudar L.V., Karnafel W., Garcia L.C., et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: The ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol 2008, 103:1182-1192.
169. Evstatiev R., Marteau P., Iqbal T., Khalif I.L., Stein J., Bokemeyer B., et al. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology 2011, 141:846-853.
170. Kim Y.T., Kim S.W., Yoon B.S., Cho H.J., Nahm E.J., Kim S.H., et al. Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy. Gynecol Oncol 2007, 105:199-204.
171. Dangsuwan P., Manchana T. Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy. Gynecol Oncol 2010, 116:522-525.
172. García-Erce J.A., Fernández C., Lao J., Muñoz M. Meta-análisis de la eficacia y seguridad de hierro endovenoso en el tratamiento de la anemia, en pacientes oncológicos tratados con agentes estimulantes de la eritropoyesis. Hematologica (edición española) 2009, 94:138.
173. Hedenus M., Birgegård G., Näsman P., Ahlberg L., Karlsson T., Lauri B., et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: A randomized multicenter study. Leukemia 2007, 21:627-632.
174. Chertow G.M., Mason P.D., Vaaga-Nilsen O., Ahlmén J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006, 21:378-382.
175. Stainsby D., Jones H., Asher D., Atterbury C., Boncinelli A., Brant L., et al. Serious hazards of transfusion: A decade of hemovigilance in the UK. Transfus Med Rev 2006, 20:272-282.
176. Feldman H.I., Joffe M., Robinson B., Knauss J., Cizman B., Guo W., et al. Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol 2004, 15:1623-1632.
177. Harju E. Empty iron stores as a significant risk factor in abdominal surgery. J Parent Enteral Nutr 1988, 12:282-285.
178. Izuel Rami M., García Erce J.A., Gómez-Barrera M., Cuenca Espiérrez J., Abad Sazatornil R., Rabanaque Hernández M.J. Relación entre la transfusión de sangre alogénica, la deficiencia de hierro y la infección nosocomial en pacientes con fractura de cadera. Med Clin (Barc) 2008, 131:647-652.
179. Laupacis A., Fergusson D. Erythropoietin to minimize perioperative blood transfusion: A systematic review of randomized trials. Transfus Med 1998, 8:309-317.
180. Feagan B.G., Wong C.J., Kirkley A., Johnston D.W.C., Smith F.C., Whitsitt P., et al. Erythropoietin with iron supplementation to prevent allogeneic blood transfusion in total hip joint arthroplasty. A randomized, controlled trial. Ann Intern Med 2000, 133:845-854.
181. Weber E.W., Slappendel R., Hémon Y., Mähler S., Dálen T., Rouwet E., et al. Effects of epoetin alfa on blood transfusions and postoperative recovery in orthopaedic surgery: The European Epoetin Alfa Surgery Trial (EEST). Eur J Anaesthesiol 2005, 22:249-257.
182. Karkouti K., McCluskey S.A., Evans L., Mahomed N., Ghannam M., Davey R. Erythropoietin is an effective clinical modality for reducing RBC transfusion in joint surgery. Can J Anaesth 2005, 52:363-368.
183. Alghamdi A.A., Albanna M.J., Guru V., Brister S.J. Does the use of erythropoietin reduce the risk of exposure to allogeneic blood transfusion in cardiac surgery? A systematic review and meta-analysis. J Card Surg 2006, 21:320-326.
184. Ootaki Y., Yamaguchi M., Yoshimura N., Oka S., Yoshida M., Hasegawa T. The efficacy of preoperative administration of a single dose of recombinant human erythropoietin in pediatric cardiac surgery. Heart Surg Forum 2007, 10:E115-E119.
185. Weltert L., D'Alessandro S., Nardella S., Girola F., Bellisario A., Maselli D., et al. Preoperative very short-term, high-dose erythropoietin administration diminishes blood transfusion rate in off-pump coronary artery bypass: A randomized blind controlled study. J Thorac Cardiovasc Surg 2010, 139:621-627.
186. Yoo Y.C., Shim K.K., Kim J.C., Jo Y.Y., Lee J.H., Kwak Y.L. Effect of single recombinant human erythropoietin injection on transfusion requirements in preoperatively anemic patients undergoing valvular heart surgery. Anesthesiology 2011, 115:929-937.
187. Qvist N., Boesby S., Wolff B., Hansen C.P. Recombinant human erythropoietin and hemoglobin concentration at operation and during the postoperative period: Reduced nee for blood transfusions in patients undergoing colorectal surgery--Prospective double-blind placebo-controlled study. World J Surg 1999, 23:30-35.
188. Kosmadakis N., Messaris E., Maris A., Katsaragakis S., Leandros E., Konstandoulakis M.M., et al. Perioperative erythropoietin administration in patients with gastrointestinal tract cancer. Prospective randomized double blind study. Ann Surg 2003, 237:417-421.
189. Christodoulakis M., Tsiftsis D.D. Preoperative epoetin alfa in colorectal surgery: A randomized, controlled study. Ann Surg Oncol 2005, 12:718-725. Hellenic Surgical Oncology Perioperative EPO Study Group.
190. Zarychansky R., Turgeron A.B., McIntyre L., Fergusson D.A. Erythropoietin-receptor agonist in critical ill patients: A meta-analysis of randomised controlled trials. CMAJ 2007, 177:725-734.
191. Muñoz M., García-Erce J.A., Leal-Noval S.R. ¿La eritropoyetina humana recombinante es aún una alternativa válida para el tratamiento de la anemia del paciente crítico?. Med Clin (Barc) 2009, 132:749-755.
192. Corwin H.L., Gettinger A., Fabian T.C., May A., Pearl R.G., Heard S., et al. Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med 2007, 357:965-976.
193. Talving P., Lustenberger T., Inaba K., Lam L., Mohseni S., Chan L., et al. Erythropoiesis-stimulating agent administration and survival after severe traumatic brain injury: A prospective study. Arch Surg 2012, 147:251-255.
194. Rosencher N., Poisson D., Albi A., Aperce M., Barré J., Samama M. Two injections of erythropoietin correct moderate anemia in most patients awaiting orthopedic surgery. Can J Anesth 2005, 52:160-165.
195. Gonzalez-Porras J.R., Colado E., Conde M.P., Lopez T., Nieto M.J., Corral M. An individualized pre-operative blood saving protocol can increase pre-operative haemoglobin levels and reduce the need for transfusion in elective total hip or knee arthroplasty. Transfus Med 2009, 19:35-42.
196. Stowell C.P., Jones S.C., Enny C., Langholff W., Leitz G. An open-label, randomized, parallel-group study of perioperative epoetin alfa versus standard of care for blood conservation in major elective spinal surgery: Safety analysis. Spine (Phila Pa 1976) 2009, 34:2479-2485.
197. Dahl N.V., Henry D.H., Coyne D.W. Thrombosis with erythropoietic stimulating agents: Does iron-deficient erythropoiesis play a role?. Semin Dial 2008, 21:210-211.
198. Basora M., Fita G., Matute P., Díaz-Ricart M. Safety concerns about perisurgical epoetin treatment: Should we add antiplatelet drugs to perisurgical epoetin alfa treatment?. J Cardiothorac Vasc Anesth 2007, 21:623-624.
199. Roberts I., Alderson P., Bunn F., Chinnock P., Ker K., Schierhout G. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev 2004, 4:CD000567.
200. Pargger H., Studer W., Ruttimann U. Volume therapy in hypotensive trauma patients. Schweiz Med Wochenschr 2000, 130:1509-1515.
201. Søreide E., Deakin C.D. Pre-hospital fluid therapy in the critically injured patient--A clinical update. Injury 2005, 36:1001-1010.
202. Nolan J. Fluid resuscitation for the trauma patient. Resuscitation 2001, 48:57-69.
203. Shafi S., Kauder D.R. Fluid resuscitation and blood replacement in patients with polytrauma. Clin Orthop Relat Res 2004, 422:37-42.
204. Santry H.P., Alam H.B. Fluid resuscitation: Past, present, and the future. Shock 2010, 33:229-241.
205. Kozek-Langenecker S.A., Jungheinrich C., Sauermann W., van der Linden P. The effects of hydroxyethyl starch 130/0.4 (6%) on blood loss and use of blood products in major surgery: A pooled analysis of randomized clinical trials. Anesth Analg 2008, 107:382-390.
206. Stainsby D., MacLennan S., Thomas D., Isaac J., Hamilton P.J. Guidelines on the management of massive blood loss. Br J Haematol 2006, 135:634-641.
207. Holcomb J.B., Wade C.E., Michalek J.E., Chisholm G.B., Zarzabal L.A., Schreiber M.A., et al. Increased plasma and platelet to red blood cell ratios improves outcome in 466 massively transfused civilian trauma patients. Ann Surg 2008, 248:447-458.
208. Nakstad A.R., Skaga N.O., Pillgram-Larsen J., Gran B., Heier H.E. Trends in transfusion of trauma victims--Evaluation of changes in clinical practice. Scand J Trauma Resusc Emerg Med 2011, 11:19-23.
209. Rajasekhar A., Gowing R., Zarychanski R., Arnold D.M., Lim W., Growther M.A., et al. Survival of trauma patients after massive red blood cell transfusion using a high or low red blood cell to plasma transfusion ratio. Crit Care Med 2011, 39:1507-1513.
210. Nascimento B., Callum J., Rubenfeld G., Neto J.B., Lin Y., Rizoli S. Clinical review: Fresh frozen plasma in massive bleedings - more questions than answers. Crit Care 2010, 14:202.
211. Stansbury L.G., Dutton R.P., Stein D.M., Bochicchio G.V., Scalea T.M., Hess J.R. Controversy in trauma resuscitation: Do ratios of plasma to red blood cells matter?. Transfus Med Rev 2009, 23:255-265.
212. Perel P., Roberts I. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev 2007, 4:CD000567.
213. Perner A., Haase N., Guttormse A.B., Tenhunen J., Klemenzson G., Aneman A., et al. Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. N Engl J Med 2012, 367:124-134. 6S Trial Group; Scandinavian Critical Care Trials Group, doi:10.256/NEJMoa1204242.
214. Riess J.G. Perfluorocarbon-based oxygen delivery. Artif Cells Blood Substit Immobil Biotechnol 2006, 34:567-580.
215. Maevsky E., Ivanitsky G., Bogdanova L., Axenova O., Karmen N., Zhiburt E., et al. Clinical results of Perftoran application: Present and future. Artif Cells Blood Substit Immobil Biotechnol 2005, 33:37-46.
216. Cohn C.S., Cushing M.M. Oxygen therapeutics: Perfluorocarbons and blood substitute safety. Crit Care Clin 2009, 25:399-414.
217. Verdín-Vasquez R.C., Zepeda-Pérez C., Ferra-Ferrer R., Chavez-Negrete A., Contreras F., Barroso-Aranda J., et al. Use of perftoran emulsion to decrease allogeneic blood transfusion in cardiac surgery: Clinical trial. Artif Cells Blood Substit Immobil Biotechnol 2006, 34:433-454.
218. Jahr J.S., Mackenzie C., Pearce L.B., Pitman A., Greenburg A.G. HBOC-201 as an alternative to blood transfusion: Efficacy and safety evaluation in a multicenter phase iii trial in elective orthopedic surgery. J Trauma 2008, 64:1484-1497.
219. Cothern C., Moore E.E., Offner P.J., Haenel J.B., Johnson J.L. Blood substitute and erythropoietin therapy in severely anemic Jehovah's witness. N Engl J Med 2002, 346:1097-1098.
220. Moore E.E., Moore F.A., Fabian T.C., Bernard A.C., Fulda G.J., Hoyt D.B., et al. Human polymerized hemoglobin for the treatment of hemorrhagic shock when blood is unavailable: The USA multicenter trial. J Am Coll Surg 2009, 208:1-13.
221. Olofsson C., Nygards E.B., Ponzer S., Fagrell B., Przybelski R., Keipert P.E., et al. A randomized, single-blind, increasing dose safety trial of an oxygen-carrying plasma expander (Hemospan) administered to orthopaedic surgery patients with spinal anaesthesia. Transfus Med 2008, 18:28-39.
222. Silverman T.A., Weiskopf R.B. Hemoglobin-based oxygen carriers: Current status and future directions. Anesthesiology 2009, 111:946-963.